Advertisement
Canada markets open in 8 hours 56 minutes

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7306
    -0.0005 (-0.06%)
     

  • CRUDE OIL

    79.78
    +0.52 (+0.66%)
     

  • Bitcoin CAD

    86,164.95
    +2,069.12 (+2.46%)
     

  • CMC Crypto 200

    1,350.78
    +50.68 (+3.90%)
     

  • GOLD FUTURES

    2,358.10
    +17.80 (+0.76%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • NASDAQ futures

    18,219.50
    +5.00 (+0.03%)
     

  • VOLATILITY

    12.69
    -13.00 (-50.60%)
     

  • FTSE

    8,381.35
    +27.30 (+0.33%)
     

  • NIKKEI 225

    38,157.48
    +83.50 (+0.22%)
     

  • CAD/EUR

    0.6778
    0.0000 (0.00%)
     

Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

Phathom Pharmaceuticals
·1 min read

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. ET.

Company management will also participate in one-on-one meetings during the virtual conference.

To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on follow the Company on social media: LinkedIn at www.linkedin.com/company/phathompharma and Twitter @PhathomPharma.

CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com